Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
This is a first-in-human study to evaluate how safe and tolerable a drug called RO7502175 is, as well as how it interacts in the body and what anti-cancer activity it has, when given by itself or in combination with atezolizumab or pembrolizumab in people with locally advanced or metastatic solid tumors, including:
- non-small-cell lung cancer (NSCLC),
- head and neck squamous cell carcinoma (HNSCC),
- melanoma,
- triple-negative breast cancer (TNBC),
- oesophageal cancer,
- gastric cancer,
- cervical cancer,
- colorectal cancer (CRC),
- urothelial carcinoma (UC),
- clear cell renal cell carcinoma (RCC) and
- hepatocellular carcinoma (HCC).
Participants will be enrolled in 2 stages: dose escalation and dose expansion. Enrollment is open only for the 1b Expansion CPI-Naive NSCLC cohort.
Conditions
This trial is treating people with locally advanced, metastatic or recurrent solid cancers
Eligibility
Inclusion
- Life expectancy at least 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
- Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
- Tumor Specimen availability
Exclusion
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment
- Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
- Active hepatitis B or C or tuberculosis
- Positive test for human immunodeficiency virus (HIV) infection
- Acute or chronic active Epstein-Barr virus (EBV) infection at screening
- Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Active or history of autoimmune disease
- Prior allogeneic stem cell or organ transplantation
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- Your cancer has not spread to other parts of the body (localised).
- Your cancer has not spread to other parts of the body, but it is not possible to perform surgery to remove it (unresectable).
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov, EU Clinical Trials Register *. View further details about this trial on the registry via the links below:
Trial sponsor
Genentech
Scientific Title
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information